Terminated PHASE3 INTERVENTIONAL 1-arm NCT01840085

Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use (STRIDE 5)

Open-Label Phase III Clinical Trial to Evaluate the Safety of 0.03% DSC127 Gel in Chronic Use for Treating Diabetic Foot Ulcers (DFU)

Sponsor: Integra LifeSciences Corporation

Conditions Diabetic Foot Ulcer

Interventions 0.03% DSC127 topical gel

Updated 9 times since 2017 Last updated: Dec 8, 2017 Started: Dec 31, 2015 Primary completion: Dec 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Integra LifeSciences Corporation

More terminations from Integra LifeSciences Corporation

Other Diabetic Foot Ulcer trials with similar outcome

Browse all Diabetic Foot Ulcer trials

Listed as NCT01840085, this PHASE3 trial focuses on Diabetic Foot Ulcer and remains terminated or withdrawn. Sponsored by Integra LifeSciences Corporation, it has been updated 9 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 4 earlier versions

Dec 2017 — Jun 2018 [monthly]

Terminated PHASE3

Status: Unknown Status → Terminated
Sep 2017 — Dec 2017 [monthly]

Unknown Status PHASE3

Status: Active Not Recruiting → Unknown Status
Feb 2017 — Sep 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Integra LifeSciences Corporation
Integrium

Data source: Integra LifeSciences Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aiken, United States , Chino, United States , Fresno, United States , Greenville, United States , Homestead, United States , Jacksonville, United States , Los Angeles, United States , Miami, United States , Miami Lakes, United States , Mobile, United States and 9 more locations